Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868264 · ClinicalTrials.gov registry record · Phase 3
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
A Phase 3 study of Hepatitis C Virus Chronic Infection, sponsored by Atea Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 880
- Enrollment target
- 20
- Study locations
NCT06868264: Active Phase 3 study of Hepatitis C Virus Chronic Infection, sponsored by Atea Pharmaceuticals.
NCT06868264 is a Phase 3 study of Hepatitis C Virus Chronic Infection that is active but no longer recruiting, run by Atea Pharmaceuticals. The registered enrollment target is 880 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06868264, a Phase 3 study of Hepatitis C Virus Chronic Infection, is active but no longer recruiting, sponsored by Atea Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 880 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Conditions Studied
Interventions
- DRUG Bemnifosbuvir-Ruzasvir (BEM/RZR)
- DRUG Sofosbuvir-Velpatasvir (SOF/VEL)
Study Locations (20)
California
- Atea Study Site - Bakersfield
- Atea Study Site - Coronado
- Atea Study Site - Escondido
- Atea Study Site - Fresno
- Atea Study Site - Long Beach
- Atea Study Site - Los Angeles
- Atea Study Site - Los Angeles
- Atea Study Site - Orange
- Atea Study Site - Pasadena
- Atea Study Site - Sacramento
- Atea Study Site - Torrance
Arizona
- Atea Study Site - Chandler
- Atea Study Site - Flagstaff
- Atea Study Site - Mesa
- Atea Study Site - Phoenix
- Atea Study Site - Phoenix
- Atea Study Site - Tucson
Alabama
- Atea Study Site - Birmingham
- Atea Study Site - Dothan
Arkansas
- Atea Study Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 880 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
What the registry record for NCT06868264 still lists
NCT06868264 is an interventional study that assigns participants to a tested intervention. The registered 880 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% higher).
The record links to 1 condition, with Hepatitis C Virus Chronic Infection appearing as the primary indexed condition, and to 2 interventions - of which Bemnifosbuvir-Ruzasvir (BEM/RZR) is the first listed.
NCT06868264 names 20 study sites across 4 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06868264 about?
NCT06868264 is a clinical study titled "C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV". The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
What is the current status of trial NCT06868264?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 880 participants. The study started on 2025-04-07. Estimated completion is 2026-12.
What conditions does trial NCT06868264 study?
This clinical trial studies the following conditions: Hepatitis C Virus Chronic Infection.
What interventions are being tested in trial NCT06868264?
The interventions under investigation include: Bemnifosbuvir-Ruzasvir (BEM/RZR) (DRUG), Sofosbuvir-Velpatasvir (SOF/VEL) (DRUG).
Who is sponsoring clinical trial NCT06868264?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06868264 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06868264's enrollment target sits among peer trials
880 367th of 2000 higher than 1,631 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
- NCT05525663 · 880 participants · NA
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
- NCT06580314 · 880 participants · Phase 3
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI